Holy Stone Healthcare’s patent “Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease” received silver award at 2020 National Invention and Creation Awards
The study result of “CA102N suppresses the growth of mouse colon cancer by inhibition of PI3K pathway and immune modulation” will be presented during the Annual Meeting of American Association of Cancer Research
Holy Stone Healthcare Co., Ltd. attended 2019 BIO International Convention in Philadelphia, USA on June 3-6.
Holy Stone Healthcare participates in the Atlanta 2019 AACR Annual Meeting (2019/3/29-4/3) poster presentation.
Holy Stone Healthcare Co., Ltd.‘s new drug for colorectal cancer, CA102N, has received from US FDA the IND approval for conducting phase I clinical trial.
Holy Stone Healthcare Co., Ltd. attended 2018 BIO International Convention in Boston, USA on June 4-7.
Holy Stone Healthcare participates in the Chicago 2018 AACR Annual Meeting (2018/4/14-4/18) poster presentation. Dr. Eskouhie Tchaparian will promote the company’s new drug, CA102N, targeting colorectal cancer.
MediWound Ltd. (Nasdaq: MDWD) has signed an agreement with Holy Stone Healthcare Co., Ltd. on October 16, 2017, granting Holy Stone Healthcare the exclusive distribution rights of NexoBrid® in Taiwan.
Holy Stone Healthcare Co., Ltd., together with representatives of MDT Int’l S.A., attended 2017 BIO International Convention in San Diego, USA. on June 19-22.
A research report of IBD98-M for inflammatory bowel disease from Holy Stone Healthcare, is published on 《Molecules》
A pre-clinical (in-vivo & in-vitro) study report from Holy Stone Healthcare's novel targeting anti-cancer drug in colorectal cancer, CA102N, is published on《Nanomedicine》, volume 2017:12 on March 27, 2017.